What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received ...

If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

In June 2026, a Delaware jury ruled that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...

Amgen (AMGN) stock is in focus as an expert panel of the European Medicines Agency recommends withdrawal of the company's ...

Adjusted EPS $4.90 vs LSEG estimate of $4.30 Revenue of $8.1 billion in line with Wall Street estimates 2025 outlook reaffirmed May 1 (Reuters) - Amgen (AMGN.O), opens new tab on Thursday said its ...

Amgen's MariTide aims for quicker weight loss, fewer doses than GLP-1 drugs Analysts expect MariTide to show at least 20% weight loss Concerns over side effects, including nausea and bone density ...

Amgen is recognized as a biotech pioneer with a long history of groundbreaking discoveries. From developing Epogen in the 1980s as one of the first recombinant DNA technology-based treatments for ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin ...